文献速递慢阻肺

无创影像生物标志物识别重度慢阻肺小气道损伤

Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

研究将离体参数反应映射(PRM)分析与重度慢阻肺肺移植患者及对照者的肺组织微CT测量相关联,发现PRMfSAD与终末细支气管数量减少、管腔狭窄和阻塞相关,PRMEmph与肺气肿指标相关,首次证实影像生物标志物可识别终末支气管病理。

要点

  • PRMfSAD可识别终末细支气管丢失、管腔狭窄和阻塞区域。
  • PRMEmph与空气腔增大、肺泡表面积减少相关。
  • 影像生物标志物为慢阻肺小气道损伤提供无创识别方法。

核心结论

  • PRMfSAD可识别终末细支气管丢失、管腔狭窄和阻塞的肺组织区域。
  • 这是首次证实影像生物标志物能在已确立的慢阻肺中识别终末支气管病理。

研究设计与样本

  • 研究将离体PRM分析与重度慢阻肺肺移植患者及对照者的活体肺组织测量相关联。
  • 切除肺充气冷冻后系统采样,生成33份慢阻肺(11例受试者)和22份对照(3例受试者)组织样本用于微CT分析。

主要发现

  • 慢阻肺肺中终末细支气管数量减少(P=0.01)。
  • 存活终末细支气管壁面积百分比增加(P<0.001)、圆度降低(P<0.001)、横截管腔面积减少(P<0.001)、气道阻塞更重(P=0.008)。
  • 慢阻肺肺空气腔尺寸增大(P<0.001)、肺泡表面积减少(P<0.001)。
  • PRMfSAD与终末细支气管圆度降低(P<0.001)、管腔面积减少(P<0.001)和完全阻塞(P=0.008)独特相关。
  • PRMEmph与空气腔尺寸增大(P<0.001)、肺泡表面积减少(P=0.003)及每个终末细支气管肺泡附着减少(P=0.01)相关。

关键数值与推荐

  • PRM分析用于区分功能性小气道疾病(PRMfSAD)与肺气肿(PRMEmph)。
  • 微CT分析终末细支气管(传导气道最后一代)和肺气肿。

临床怎么用

  • PRMfSAD可作为无创影像方法识别慢阻肺小气道损伤。
  • PRMEmph可用于评估肺气肿相关结构改变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Evidence suggests damage to small airways is a key pathologic lesion in chronic obstructive pulmonary disease (COPD). Computed tomography densitometry has been demonstrated to identify emphysema, but no such studies have been performed linking an imaging metric to small airway abnormality.Objectives: To correlate ex vivo parametric response mapping (PRM) analysis to in vivo lung tissue measurements of patients with severe COPD treated by lung transplantation and control subjects.Methods: Resected lungs were inflated, frozen, and systematically sampled, generating 33 COPD (n = 11 subjects) and 22 control tissue samples (n = 3 subjects) for micro-computed tomography analysis of terminal bronchioles (TBs; last generation of conducting airways) and emphysema.Measurements and Main Results: PRM analysis was conducted to differentiate functional small airways disease (PRMfSAD) from emphysema (PRMEmph). In COPD lungs, TB numbers were reduced (P = 0.01); surviving TBs had increased wall area percentage (P < 0.001), decreased circularity (P < 0.001), reduced cross-sectional luminal area (P < 0.001), and greater airway obstruction (P = 0.008). COPD lungs had increased airspace size (P < 0.001) and decreased alveolar surface area (P < 0.001). Regression analyses demonstrated unique correlations between PRMfSAD and TBs, with decreased circularity (P < 0.001), decreased luminal area (P < 0.001), and complete obstruction (P = 0.008). PRMEmph correlated with increased airspace size (P < 0.001), decreased alveolar surface area (P = 0.003), and fewer alveolar attachments per TB (P = 0.01).Conclusions: PRMfSAD identifies areas of lung tissue with TB loss, luminal narrowing, and obstruction. This is the first confirmation that an imaging biomarker can identify terminal bronchial pathology in established COPD and provides a noninvasive imaging methodology to identify small airway damage in COPD.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Vasilescu DM, Martinez FJ, Marchetti N, et al. Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2019. PMID: 30794432. doi:10.1164/rccm.201811-2083OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。